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Bisphosphonates are used in patients with metastatic bone disease to 
prevent skeletal-related events (SREs) such as bone pain, fractures and 
spinal cord or nerve compression and hypercalcemia of malignancy. 
(1) Bisphosphonates are synthetic analogs of pyrophosphate. The four 
bisphosphonates used are Clodronate, Pamidronate, Zoledronic acid 
and Ibandronate. (2) The latter drug is the newest and it is used outside 
of the U.S. since it has not been approved yet by the U.S. Food and 
Drug Administration.
Bisphosphonates work mainly by inhibiting normal and pathologic 
osteoclast-mediated bone resorption thereby preventing bone loss. They 
do this by accumulating in sites of active bone formation making the 
sites more resistant to dissolution by osteoclasts.
In lung cancer patients who die from their disease, 30%-40% will be 
diagnosed with bone metastases. The majority of these patients will 
have symptomatic bone involvement.
In the U.S., Zoledronic acid, 4 mg infused for 15 minutes every 3-4 
weeks is used to treat lung cancer patients with metastatic bone disease. 
In a randomized phase III double-blind, placebo controlled trial, in 
patients with non-small cell lung cancer (NSCLC) and other solid 
tumors, in a 21-month follow-up of the patients, the patients receiv-
ing Zoledronic acid, 4 mg experienced less SRE’s (38%) compared to 
the patients receiving the placebo (47%).(3) Median times to ﬁrst SRE 
were 230 days and 163 days respectively.
Bisphosphonates are generally well tolerated. The most common side 
effects include ﬂu-like symptoms (e.g. fever, myalgia, arthralgia) oc-
curring in 10%-20% of patients which usually occurs 12 to 48 hours 
after the infusion and lasting 6 to 24 hours. Other side effects include 
bone pain, weakness, anemia, nausea, dyspnea and peripheral edema. 
These are usually mild to moderate. Ocular effects include uveitis 
which is rare. Oral bisphosphonates are generally associated with gas-
trointestinal intolerance, esophagitis and diarrhea.
Two more serious complications include renal dysfunction and osteo-
necrosis of the jaw (ONJ). Since all bisphosphonates undergo renal 
clearance, their administration may result in elevated serum creatinine 
levels. Therapy should be withheld with increase in serum creatinine 
levels > 0.5 mg/dL above upper limits of normal. ONJ is a rare disorder 
characterized by temporary or permanent lose of blood supply to the 
jaw resulting in the development of necrotic bone in the mandible or 
maxilla. Symptoms include pain, swelling or infection of gums, loosen-
ing of teeth and poor healing of the gums. To minimize the risk of ONJ, 
patients must maintain excellent oral hygiene, limit alcohol and tobacco 
use, obtain dental assessments prior to starting bisphosphonates and 
avoid dental procedures while being treated with bisphosphonates. 
Bisphosphonates should be discontinued for 3 months prior to undergo-
ing a dental procedure.
Future development of the use of bisphosphonates include (1) trials 
investigating whether high-dose bisphosphonates can reduce metastatic 
bone pain, (2) studies of adjuvant therapy with bisphosphonates in 
order to prevent bone metastases and (3) Use of bisphosphonates to 
prevent cancer-therapy induced bone loss.
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Surgical treatment of bone metastases
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Approximately 30-40% of all lung cancer patients will develop bone 
metastases during the course of their disease and the care for these 
patients has drawn increased attention during the last decade. In ortho-
pedic practice there is increased demand for reconstructive surgery for 
pathological fracture and for paraplegia due to spinal cord compression. 
By applying surgical techniques developed in joint arthroplasty, trauma 
surgery, degenerative spinal disease and limb sparing surgery, the or-
thopedic surgeon is well armed for restoring function to cancer patients 
with skeletal complications.
Survival
Bone metastases often dramatically affect quality of life by causing 
pain, pathologic fracture, hypercalcemia, anemia and paraparesis. 
These complications often occur during the last months of life; howev-
er, some patients will live for years. It would be of clinical importance 
if this subgroup of patients could be identiﬁed since the reconstructive 
procedure for a patient who will survive 2 months should not neces-
sarily be the same as for one who will live 2 years. We have recently 
performed a study of a consecutive series of 100 lung cancer patients 
treated surgically for metastatic lesions from 1986 through 2006. 
Sixty-eight patients were surgically treated for a long bone fracture and 
thirty-two patients due to paraparesis. We found that only 19% of the 
patients were living one year after surgery and 7% after two years. The 
median survival was 319 days for patients with adenocarcinoma, 253 
days for patients with SCLC and 244 days for squamous cell carci-
noma. One of three patients had skeletal metastasis as the ﬁrst sign of 
